Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Listen on:
Episodes
Thursday Mar 02, 2023
Thursday Mar 02, 2023
Discussing the management using the algorithm of Small Cell Lung Cancer (SCLC) – with Dr. Estelamari Rodriguez, Associate Director of Community Outreach - Thoracic Oncology at Sylvester Comprehensive Cancer Center - University of Miami Health System.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Monday Feb 27, 2023
Monday Feb 27, 2023
Discussing the MOUNTAINEER Phase II study, which resulted in the FDA approval of the Tucatinib and Trastuzumab combination for advanced colorectal cancer HER2 positive patients. In discussion with the lead author, Dr. Tanios S. Bekaii-Saab - Medical Oncology Chief, Leader of Enterprise Wide GI Cancer Program at Mayo Clinic Comprehensive Cancer Center.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Wednesday Feb 22, 2023
Wednesday Feb 22, 2023
Discussing GU ASCO 2023 Highlights - practice changing / informing studies with Dr. Petros Grivas, Clinical Director of Genitourinary Cancer Program, Professor, Division of Medical Oncology at Fred Hutch Cancer Center.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Feb 09, 2023
Thursday Feb 09, 2023
Discussing the management using the algorithm of Prostate Cancer – with Dr. Neeraj Agarwal, Director of Genitourinary Oncology Program - Professor of Medicine at Huntsman Cancer Institute at University of Utah.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Feb 02, 2023
Thursday Feb 02, 2023
Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with the lead author, Dr. Aditya Bardia - Associate Professor at Massachusetts General Hospital - Harvard Medical School.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Jan 26, 2023
Thursday Jan 26, 2023
Discussing GI ASCO 2023 Highlights - practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare.
SPOTLIGHT - Zolbetuximab with mFOLFOX6 Meets Primary Endpoint
NAPOLI3 - Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer
MOUNTAINEER - FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
SUNLIGHT - Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Monday Jan 16, 2023
Monday Jan 16, 2023
The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi - Medical Oncologist at the Netherlands Cancer Institute.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Friday Jan 13, 2023
Friday Jan 13, 2023
Discussing the management of Bladder Cancer using an algorithm – with Dr. Andrea Apolo, Chief of Bladder Cancer - Genitourinary Malignancy at the National Cancer Institute.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Jan 05, 2023
Thursday Jan 05, 2023
Discussing the management using the algorithm of Kidney Cancer or Renal Cell Cancer (RCC) – with Dr. Elizabeth Plimack, Deputy Director, Fox Chase Cancer Center – Temple Health, Director – Genitourinary Clinical Research, Temple University Health System.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Friday Dec 30, 2022
Friday Dec 30, 2022
Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi - Professor of Medicine at Memorial Sloan Kettering Cancer Center.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com